| Ondansetron Hydrochloride Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Ondansetron Hydrochloride 8 mg | tablet | oral | 1.0 each | OTC |
| Ondansetron Hydrochloride 24 mg | tablet | oral | 1.0 each | OTC |
| Ondansetron Hydrochloride 4 mg | tablet | oral | 1.0 each | OTC |
| Ondansetron Hydrochloride 4 mg/5 mL | solution | oral | 5.0 milliliter(s) | OTC |
| Ondansetron Hydrochloride 2 mg/mL | solution | injectable | 1.0 milliliter(s) | OTC |
| Ondansetron Hydrochloride 32 mg/50 mL | solution | intravenous | 50.0 milliliter(s) | OTC |
| Ondansetron Hydrochloride 8 mg | tablet, disintegrating | oral | 1.0 each | OTC |
| Ondansetron Hydrochloride 4 mg | tablet, disintegrating | oral | 1.0 each | OTC |
Eurand Q4 Loss Widens On Higher Costs - RTT News
Eurand intends to discuss the further development of EUR-1025, the company's proprietary once-a-day oral formulation of ondansetron hydrochloride, ...
Thu Mar 06 13:52:32 -0500 2008
Eurand Reports Fourth Quarter and Year-end 2007 Key Achievements ... - Ad-Hoc-News (Pressemitteilung)
Ondansetron hydrochloride is marketed under the brand nameZofran(r) by GSK for the treatment and prevention ofchemotherapy-induced nausea and vomiting. ...
Fri Mar 07 11:11:47 -0500 2008
EURX: Positive Pharmacokinetic Study re Ondansetron vs GSK's Zofran(R) - Trading Markets (press release)
Ondansetron hydrochloride is marketed under the brand name Zofran(R) by GlaxoSmithKline for the treatment and prevention of chemotherapy-induced nausea and ...
Tue Feb 26 10:34:10 -0500 2008
ondansetron hydrochloride - The hydrochloride salt of the racemic form of ondansetron, a carbazole derivative and a selective, competitive serotonin 5-HT3 receptor antagonist with antiemetic properties. Although its mechanism of action has not been fully characterized, ondansetron appears to competitively block the action of serotonin at 5HT3 receptors peripherally in the gastrointestinal tract as well as centrally in the area postrema of the CNS (the chemoreceptor trigger zone for vomiting), resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.